Advertisement

ASCO GI 2024: Radioligand Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Posted: 01/31/2024 | By: Chase Doyle

The phase III NETTER-2 study evaluated Lu-177 dotatate as first-line treatment in patients with grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors. Results were presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract LBA588).

Question 1 of 5

What are the primary and secondary endpoints of the NETTER-2 study?

Choose 1

A
The primary endpoint is overall survival and the secondary endpoint is disease progression
B
The primary endpoint is disease progression and the secondary endpoint is treatment side effects
C
The primary endpoint is progression-free survival and the secondary endpoint is objective response rate
D
The primary endpoint is overall response rate and the secondary endpoint is progression-free survival

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage